Background: Although sinus node dysfunction is primarily related to degenerative fibrosis of
Introduction
Sinus node dysfunction is a frequent cardiac disorder in the elderly that may occur due to intrinsic causes (abnormality of impulse generation/formation or propagation because of agerelated fibrosis, coronary artery disease, etc.) or extrinsic causes (pharmacologic agents, electrolyte imbalances, autonomic nervous system dysfunction, hypothyroidism, hypothermia, etc.). ECG manifestations include sinus bradycardia, sinus arrest, sinoatrial block, atrial fibrillation with slow ventricular response, and bradycardia-tachycardia syndrome. More than one manifestation can occur in the same patient on different occasions (1) . In the present case, antipsychotic agents were suspected of inducing sinus node dysfunction.
Case report
A 53-year-old woman was referred to the cardiology department with severe fatigue and a slow heart rate. Her past medical history included lumbar spondylosis, hyperlipidemia, Her physical examination was remarkable for obesity (BMI 31.9), tremor and bradycardia with a heart rate of 45 beats per minute. A complete blood count, repeated serum troponin T, serum electrolyte levels measurements, and tests of kidney, liver, and thyroid function were all normal. An ECG on admission showed sinus bradycardia and junctional escape rhythm.
Mobitz II type second degree sinoatrial block was later observed (Fig.1,2) . She was admitted to a coronary care unit to permit continuous ECG monitoring. One hour later temporary pacing was applied using an external transvenous pacemaker due to the evolving symptomatic 7-second-long sinus arrest (Fig.3) . Because the patient attempted suicide two years earlier, giving up lithium was inadvisable.
Lithium's antisuicidal effect is independent from its mood-stabilising property; and lithium evidently lowers suicide mortality even in moderate and poor responders (2) . Whereas suicide-prevention effects have not been shown for long-term anticonvulsant treatment (3).
Consequently, carbamazepine administration was discontinued. Normal sinus rhythm gradually returned in two days, with a heart rate of 70 beats per minute. The temporary pacemaker was switched off on the third day. Continuous ECG monitoring showed stable sinus rhythm during the following days until the patient was discharged. ECG showed negative T waves in leads I, II, V2-5, but the exercise stress test results and thallium scans did not reveal significant coronary artery disease. Therefore, these repolarization abnormalities could be in connection with a transient change in the direction of cardiac activation due to ventricular pacing that might persist for a while after the end of pacing (cardiac memory phenomenon). The patient was discharged in a good general condition after nine days, she did not consent to coronary angiography. A cardiology control examination found normal sinus rhythm three months later. In the coronary care unit, continuous ECG monitoring was carried out that revealed intermittent sinus bradycardia with a heart rate of 45 bpm. Occasional episodes of sinus arrest (with a maximum of 2.6 s) also occurred with junctional escape beats followed by short episodes of atrial fibrillation or atrial tachycardia (Fig.4) .
Ketoconazole was discontinued. The patient's mental status did not allow giving up her antipsychotic or antidepressant therapy. Temporary pacing was not necessary at this time, sinus rhythm with a heart rate of 60 bpm returned in one day and remained stable. Four days later, she was discharged in a good condition. Because cessation of the antipsychotic and antidepressant therapy was not possible, one month later a permanent VVI pacemaker was implanted to prevent subsequent bradyarrhythmia episodes.
Discussion
This patient presented two episodes of symptomatic sinus node dysfunction with different ECG manifestations (sinus bradycardia, Mobitz II second degree sinoatrial block, sinus arrest, tachycardia-bradycardia syndrome). Though not fully ruled out, intrinsic causes were unlikely because of the relative young age, negative history for angina pectoris and normal results with noninvasive tests (echocardiography, exercise stress test, and thallium scan) that did not demonstrate coronary artery disease. Thyroid stimulating hormone was in the normal range with substitution, excluding hypothyroidism as a cause. The patient was not on medication with well-known sinus node function affecting action (digitalis, beta-blockers, non-dihidropyridine calcium channel blockers, antiarrhythmic drugs) but her medications included psychotropic agents that might explain the bradycardia.
Lithium carbonate is frequently used for the treatment of manic-depressive disorders, without significant cardiotoxicity in most patients. However, chronic lithium therapy has been associated with a wide range of cardiac side effects, including asymptomatic electrocardiographic changes, sinoatrial, and atrioventricular conduction disturbances, tachyarrhythmias, myocarditis and congenital heart disease (4). Reversible T-wave flattening and subclinical or symptomatic sinus node dysfunction are the most frequently reported cardiac abnormalities. Conduction abnormalities may occur even at subtherapeutic serum lithium levels (5).
Carbamazepine, a drug used primarily for the treatment of epilepsy, neuralgias and bipolar disorder, was also reported to exert cardiac side effects. Sinus node dysfunction, atrioventricular block, and bradycardia-tachycardia syndrome have been observed during carbamazepine treatment when used alone or when coadministered with lithium (6-8). The mechanism is unclear, though, in animal models, carbamazepine was shown to block cardiac Na + channels in a frequency-independent manner (9). Most case reports describe bradyarrhythmias in elderly women even at therapeutic carbamazepine serum levels (10).
Quetiapine, an atypical antipsychotic agent, is usually well tolerated and possesses minimal proarrhythmic effects (11) . However, QTc prolongation and first-degree atrioventricular block were reported with quetiapine overdose (12, 13) . Moreover, sinus bradycardia has been observed in two quetiapine-treated patients without QT interval prolongation (14, 15) .
Quetiapine is extensively metabolized by the cytochrome P450 system, primarily by CYP3A (16) . Concomitant administration with ketoconazole, a potent CYP3A4 inhibitor, may lead to a significant reduction in the first-pass metabolism and hepatic clearance of quetiapine and thus potentially increase adverse effects. Coadministration of ketoconazole increased mean
Cmax of quetiapine by 3.35-fold and decreased its clearance by 84% in vivo (17) .
Ketoconazole is also an inhibitor of P-glycoprotein (Pgp) and may increase plasma concentrations of Pgp substrates (18) . Quetiapine has been suggested to be a substrate for this transporter (19) . On the contrary, Grimm et al. demonstrated that quetiapine is not a substrate of Pgp (17) . Therefore, the interaction is likely to take place only on the metabolic level.
On the other hand, coadministration of carbamazepine, a potent CYP3A4 inductor, leads to a decrease in serum levels and clinical efficacy of quetiapine (17) . In the present case, discontinuation of carbamazepine after the first episode might also have increased quetiapine serum levels.
Selective serotonin reuptake inhibitors (SSRIs) are the first line therapy for depression and anxiety due to their tolerability. In contrast to tricyclic antidepressants, long-term SSRI therapy is not associated with an elevated risk of cardiovascular disease (20 
